27F, 1320-10, Seocho 2-dong, Seocho-gu
104 articles about Samsung Biologics
Samsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy
Samsung Biologics (207940.KS), the world's leading contract development and manufacturing organization, continues its strategic biopharmaceutical manufacturing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN).
Moderna COVID-19 Vaccine Manufactured in Korea by Samsung Biologics Receives Marketing Authorization from Ministry of Food and Drug Safety of Korea
Moderna, a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that the Ministry of Food and Drug Safety of Korea has issued a marketing authorization for Spikevax®, Moderna's COVID-19 vaccine manufactured by Samsung Biologics, a leading global CDMO providing fully integrated end-to-end contract development and manufacturing services.
Samsung Biologics adds to global ISO certifications with Quality Management System
Samsung Biologics, the world's leading contract development and manufacturing organization, held an award ceremony with the British Standard Institution at its Songdo headquarters for global ISO9001 certification in recognition of the company's Quality Management System.
GreenLight Biosciences and Samsung Biologics announce collaboration to build capacity for messenger RNA Vaccine Manufacturing
GreenLight Biosciences and Samsung Biologics announced a partnership agreement in which Samsung Biologics will manufacture GreenLight's messenger RNA COVID-19 vaccine candidate at commercial scale.
Samsung Biologics Reports Third Quarter 2021 Financial Results
Samsung Biologics, a leading contract development and manufacturing organization, announced record-high financial results for the third quarter of fiscal 2021.
Enzolytics Inc. and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies
Enzolytics Inc. to leverage Samsung Biologics' development and manufacturing expertise to advance both Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies to IND.
Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021, offering expedited timeline to IND and BLA
Samsung Biologics, a global contract development and manufacturing organization, introduced its proprietary technology platform, S-CellerateTM, at the BioProcess International Conference to offer clients an integrated and seamless drug development solution resulting in accelerated timelines.
Samsung Biologics Reports Second Quarter 2021 Financial Results
Samsung Biologics, the world's leading contract development and manufacturing organization, announced strong financial results for the second quarter of fiscal 2021.
Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA Antibody Immunotherapy
Kineta to leverage Samsung Biologics' development and manufacturing expertise to advance KVA12.1 to IND Samsung Biologics San Francisco R&D center and South Korea headquarters to offer a seamless, end-to-end CDMO service.
Over a year into the global pandemic, Samsung Biologics continues to leverage innovative virtual platform for remote audits and regulatory inspections
Samsung Biologics, a global contract development and manufacturing organization, celebrated the one-year mark of Live Virtual Tour, a real-time interactive platform to provide remote site inspections for both clients and regulatory agencies.
Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate
Samsung Biologics, the world's leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins.
Samsung Biologics to add mRNA vaccine drug substance manufacturing suite to expand portfolio of services
Samsung Biologics, a global leading CDMO, will add mRNA vaccine DS production capability to its existing facility by the first half of 2022
Samsung Biologics Adds Four Global ISO Certifications For BCMS, Energy, Health & Safety, and Environmental Management
Expanding upon its existing ISO22301 certification, Samsung Biologics is now fully certified with Business Continuity Management System for Security and Resilience across all business areas Samsung Biologics adds ISO50001, ISO45001, ISO14001 for Energy Management, Occupational Health and Safety, and Environmental Management to its certifications
Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine
The agreement will further enable global supply of mRNA-1273, Moderna's COVID-19 vaccine with Samsung Biologics' fill and finish manufacturing service
Global Roundup: UK Expands Life Sciences Ecosystem with Formation of We Are Pioneering Group
4/29/2021Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Samsung Biologics Reports First Quarter 2021 Financial Results
Samsung Biologics, the world's leading contract development and manufacturing organization, announced financial results for the first quarter of fiscal 2021.
Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale Manufacture of Ublituximab
Expanding upon an existing contract manufacturing deal first entered into in 2018; collaboration will further enable global manufacturing of ublituximab
Samsung Biologics Celebrates Its 10th Anniversary with Its Mission, Driven. For Life
Samsung Biologics, the world's leading contract development and manufacturing organization, celebrated the 10 th anniversary of its founding today at its global headquarters in Songdo, Incheon via a virtual ceremony.
Samsung Biologics Unveils Strong Performance and Future Plans at its 10th Annual General Meeting of Shareholders
Samsung Biologics announced a strong year in 2020 as it reported 1 trillion won in target sales within just a decade at its 10th Annual General Meeting on March 19th Korea time.
Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA
Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company's track record as a premiere CDO service provider in the global market.